HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $105 to $125.